secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2023-12-28T23:59:59+00:00
Accession:  0001193125-23-305161
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene enters up to $50M term loan with Hercules Capital; draws $22.5M initially
--------------------------------------------------------------------------------

- Up to $50M term loan, initial $22.5M drawn, $8.6M refinances prior debt.
- Interest: prime+0.75% (cap 9.75%) or 9.25% cash, plus 1.15% PIK.
- Maturity Jan 1, 2028; interest-only until July 2025, extendable to Jan 2026 or Jul 2026 if milestones met.
- Warrants to lenders for 2% of principal at $7.21 strike; 62,413 warrants issued initially.
- Negative covenants restrict additional debt, liens, dividends, acquisitions, and IP sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000119312523305161/0001193125-23-305161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000119312523305161/d680407d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-305161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer